Protein delivery system using human papillomavirus virus-like particles
View Patent ↗Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.
1. A method of delivering a peptide or protein to a cell comprising:
a) fusing a nucleic acid sequence encoding the peptide or protein to a modified human papillomavirus (HPV) L2 gene to create a fusion protein gene;
b) expressing the fusion protein gene in a host cell to obtain fusion protein;
c) contacting the fusion protein with HPV L1 protein under conditions wherein the fusion protein and the L1 protein spontaneously combine to form a virus like particle (VLP); and
d) delivering the VLP to the cell;
(i) wherein the modified HPV L2 gene encodes less than about 50% of wild type L2 protein and encodes domains from the amino and the carboxyl termini; and
(ii) wherein the HPV L2 gene is from an HPV strain selected from the group consisting of: HPV6a, HPV6b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, and HPV56.
2. A HPV virus-like particle (VLP) comprising HPV L1 protein and a fusion protein wherein the fusion protein comprises:
a first protein which is an HPV L2 protein which is less than about 50% of wild type; and
a second protein or peptide.
3. A VLP according to claim 2 wherein the HPV L2 protein is from a HPV strain selected from the group consisting of: HPV6 a, HPV6 b, HPV11, HPV16, HPV18, HPV31, HPV33, HPV35, HPV42, HPV43, HPV44, HPV45, HPV51, HPV52, and HPV56.
4. A host cell comprising the VLP of claim 2 .
5. A nucleic acid encoding a VLP according to claim 3 .